# NCT01942837 (NCT01942837)

> Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: enzalutamide
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01942837
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: Enzalutamide
- Enrollment: 67
- Primary outcome: Number of Patients With Gene Alterations

## Indexed commentary on NCT01942837 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct01942837